TY - JOUR
T1 - Compatibility of ciprofloxacin with commercial peritoneal dialysis solutions
AU - Kussmann, Manuel
AU - Ferth, Alexander
AU - Obermüller, Markus
AU - Pichler, Petra
AU - Zeitlinger, Markus
AU - Wiesholzer, Martin
AU - Burgmann, Heinz
AU - Poeppl, Wolfgang
AU - Reznicek, Gottfried
N1 - Publisher Copyright:
© 2019, The Author(s).
PY - 2019/12/1
Y1 - 2019/12/1
N2 - Intraperitoneal administration of antibiotics together with peritoneal dialysis fluids (PDFs) remains the preferable route for treatment of peritoneal dialysis-related peritonitis. For home based therapy, antibiotic-containing PDFs are stored for up to two weeks and warmed up to body-temperature before administration. The present study investigated the compatibility of ciprofloxacin with five commercial PDFs at refrigeration-temperature, room-temperature and body-temperature. Ciprofloxacin concentrations were determined using high-performance liquid chromatography. Drug-diluent stability was evaluated by measurement of pH-values and visual inspection at each sampling point. The antimicrobial activity of ciprofloxacin was assessed by an E. coli disk diffusion method. Ciprofloxacin was stable at refrigeration-temperature and body-temperature in all PDFs evaluated over the whole study period of 14 days and 24 hours, respectively. At room-temperature, in contrast, ciprofloxacin demonstrated only limited stability in particular when tested in mixed Physioneal. Except for Physioneal 1.36%, no relevant drug adsorption was observed and the antimicrobial activity of ciprofloxacin was found to be preserved in each PDF at each storage condition investigated. Intraperitoneal ciprofloxacin might be used for inpatient and home based therapy of peritoneal dialysis-related peritonitis and no compensatory dose adjustment is needed when stored for up to two weeks at refrigeration-temperature before use.
AB - Intraperitoneal administration of antibiotics together with peritoneal dialysis fluids (PDFs) remains the preferable route for treatment of peritoneal dialysis-related peritonitis. For home based therapy, antibiotic-containing PDFs are stored for up to two weeks and warmed up to body-temperature before administration. The present study investigated the compatibility of ciprofloxacin with five commercial PDFs at refrigeration-temperature, room-temperature and body-temperature. Ciprofloxacin concentrations were determined using high-performance liquid chromatography. Drug-diluent stability was evaluated by measurement of pH-values and visual inspection at each sampling point. The antimicrobial activity of ciprofloxacin was assessed by an E. coli disk diffusion method. Ciprofloxacin was stable at refrigeration-temperature and body-temperature in all PDFs evaluated over the whole study period of 14 days and 24 hours, respectively. At room-temperature, in contrast, ciprofloxacin demonstrated only limited stability in particular when tested in mixed Physioneal. Except for Physioneal 1.36%, no relevant drug adsorption was observed and the antimicrobial activity of ciprofloxacin was found to be preserved in each PDF at each storage condition investigated. Intraperitoneal ciprofloxacin might be used for inpatient and home based therapy of peritoneal dialysis-related peritonitis and no compensatory dose adjustment is needed when stored for up to two weeks at refrigeration-temperature before use.
KW - Anti-Bacterial Agents/chemistry
KW - Biocompatible Materials/chemistry
KW - Chromatography, High Pressure Liquid
KW - Ciprofloxacin/chemistry
KW - Dialysis Solutions/chemistry
KW - Drug Stability
KW - Escherichia coli/drug effects
KW - Humans
KW - Hydrogen-Ion Concentration
KW - Peritoneal Dialysis/adverse effects
KW - Peritonitis/drug therapy
KW - Temperature
UR - http://www.scopus.com/inward/record.url?scp=85064739673&partnerID=8YFLogxK
U2 - 10.1038/s41598-019-42854-y
DO - 10.1038/s41598-019-42854-y
M3 - Journal article
C2 - 31019280
SN - 2045-2322
VL - 9
SP - 6512
JO - Scientific Reports
JF - Scientific Reports
IS - 1
M1 - 6512
ER -